- Ibrahim Aqil, the Hezbollah elite unit commander wanted by the US
- Chinese forward Cui signs NBA contract with Brooklyn Nets
- US Fed dissenter calls for 'measured' pace of rate cuts
- Guardiola tells players to lead change over workload as Kompany demands cap on games
- Norway limits wild salmon fishing as stocks hit new lows
- Top Hezbollah commander killed in Israeli strike on Beirut
- Rotterdam fatal knife attacker suspected of 'terrorist motive'
- First early votes cast in knife-edge US presidential election
- Top-ranked Swiatek out of Beijing due to 'personal matters'
- Hard-right Reform UK looks to the future after vote success
- Embiid agrees to NBA contract extension with 76ers
- Joshua aims to complete road to redemption in Dubois bout
- World champion Bagnaia sets pace with lap record at Misano
- Biden says 'working' to get people back to homes on Israel-Lebanon border
- Pope criticises Argentina's crackdown on protesters
- Court limits screenings of videos in France mass rape case
- Gurbaz century takes Afghanistan to 311-4 in 2nd ODI
- Central banks face 'difficult balancing act': IMF chief
- McLaren's Norris sets Singapore pace as struggling Verstappen 15th
- Guardiola tells players to lead change over workload fears
- Paris Olympics sports equipment moves to new homes
- 'Happy' Kinghorn relishing life at Toulouse
- Norris sets Singapore pace as Verstappen only 15th
- 8 dead in Israeli strike, source says Hezbollah commander killed
- Germany to bid to host women's Euro 2029
- Portugal brings deadly forest fires under control
- Postecoglou defends Solanke after slow start to Spurs career
- US nuclear plant Three Mile Island to reopen to power Microsoft
- Arteta urges Arsenal to take next step in Man City showdown
- Stock markets fall after Fed-fuelled rally
- Top Hezbollah commander 'killed' in Israel strike
- Poland charges Russian over attack on Navalny ally: prosecutors
- Man City have rest 'advantage' in Arsenal showdown: Guardiola
- Maresca has 'no doubt' in Jackson as Chelsea's number nine
- EU chief announces 35 bn euro loan plan for Ukraine before winter
- From TikTok to Hollywood, the irresistible rise of Italy's Khaby Lame
- Verstappen punished for swearing in Singapore press conference
- Sri Lanka lead by 202 in first New Zealand Test
- Brook 'not too fussed' by England's batting in heavy Australia loss
- India's Ashwin 'happy' to embrace pressure
- A modern 'Trojan Horse': two days of mayhem in Lebanon
- Third of Burundi mpox cases in children under five: UN
- Man Utd appoint Foster + Partners to develop Old Trafford 'masterplan'
- Israel-Hezbollah exchanges intensify on Lebanon border
- French mayor sorry for 'no one died' remark over mass rape trial
- Mohamed Al-Fayed, outsider shunned by British high society
- Lawyers say 'monster' late Harrods owner abused dozens of women
- India in box seat after Bumrah takes four against Bangladesh
- Taiwan retains death penalty but limits use to 'exceptional' cases
- Ferrari's Leclerc sets early pace in Singapore ahead of Norris
CMSC | 0.12% | 25.15 | $ | |
BCC | -1.69% | 142.29 | $ | |
RYCEF | 0.14% | 6.96 | $ | |
RELX | -0.38% | 47.95 | $ | |
NGG | 1.1% | 69.595 | $ | |
CMSD | 0.16% | 25.05 | $ | |
RIO | -2.53% | 63.57 | $ | |
JRI | -0.75% | 13.3 | $ | |
SCS | -2.7% | 12.96 | $ | |
RBGPF | 5.79% | 60.5 | $ | |
GSK | -1.75% | 40.905 | $ | |
BTI | -0.54% | 37.369 | $ | |
VOD | -0.45% | 10.015 | $ | |
AZN | -0.69% | 78.36 | $ | |
BCE | -1.03% | 34.83 | $ | |
BP | -0.37% | 32.639 | $ |
Study confirms AstraZeneca jab's higher risk of very rare clot
AstraZeneca's Covid vaccine has been linked to a 30-percent higher risk of getting a very rare blood clotting condition compared to the Pfizer jab, a large international study said Thursday.
Several countries have already altered their advice after previous research indicated that -- in a tiny number of cases -- thrombosis with thrombocytopenia syndrome (TTS) can be a possible side effect of Covid vaccines that use an adenovirus vector, or "engineered" virus, such as those from AstraZeneca and Johnson & Johnson.
Thrombocytopenia produces potentially life-threatening blood clots with low levels of blood platelets -- the small cell fragments in our blood that prevent bleeding.
The new study, published in the journal BMJ, was the first to compare thrombocytopenia rates between adenovirus and mRNA vaccines -- such as Pfizer -- across multiple countries.
The international research team analysed health data from more than 10 million adults in France, Germany, the Netherlands, Spain, the United Kingdom and the United States who received at least one vaccine dose between December 2020 and mid-2021.
In Germany and the UK, they matched the data of 1.3 million people who had a first dose of AstraZeneca to 2.1 million who took Pfizer.
There were a total of 862 "thrombocytopenia events" recorded in the 28 days after a first dose of AstraZeneca, compared to 520 for Pfizer, the study said.
That meant AstraZeneca's vaccine had a 30-percent higher risk of thrombocytopenia than Pfizer.
However when it came to a second dose, there was no additional risk between any of the vaccines.
The study was observational, meaning it could not show cause and effect. But the researchers said that additional analysis found the results to be consistent.
While very rare, these risks "should be considered when planning further immunisation campaigns and future vaccine development," the study said.
- 'Safe and effective' -
Sarah Pitt, a microbiologist at the UK's Brighton University who was not involved in the research, said the "well-designed" study "adds to the data showing that all vaccines are safe and effective".
The "extremely rare" cases of thrombocytopenia occurred after just 0.04 percent of vaccine doses in Germany and the UK, she told AFP.
Most countries had already been avoiding using adenovirus Covid vaccines for the older and young age groups who are more at risk, she added.
European countries have largely pivoted towards mRNA vaccines. AstraZeneca's jab was never authorised in the US, which limited the use of the Janssen (Johnson & Johnson) COVID-19 jab to certain individuals earlier this year
However both AstraZeneca and Johnson & Johnson's vaccines play a pivotal role in Covax global vaccine distribution scheme, which provides doses to lower-income countries.
D.Sawyer--AMWN